Analysts expect NuCana PLC (NASDAQ:NCNA) to announce ($0.26) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NuCana’s earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.28). The company is scheduled to report its next earnings report on Monday, January 1st.
Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for NuCana.
Separately, Cowen reiterated a “buy” rating on shares of NuCana in a research report on Wednesday, August 29th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.00.
A number of large investors have recently modified their holdings of NCNA. Alps Advisors Inc. grew its holdings in NuCana by 8.2% in the 2nd quarter. Alps Advisors Inc. now owns 46,269 shares of the company’s stock worth $879,000 after acquiring an additional 3,508 shares during the last quarter. Asymmetry Capital Management L.P. grew its holdings in NuCana by 18.4% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 47,872 shares of the company’s stock worth $910,000 after acquiring an additional 7,424 shares during the last quarter. Woodford Investment Management Ltd grew its holdings in NuCana by 27.3% in the 2nd quarter. Woodford Investment Management Ltd now owns 420,000 shares of the company’s stock worth $7,980,000 after acquiring an additional 90,000 shares during the last quarter. Baillie Gifford & Co. grew its holdings in NuCana by 16.6% in the 1st quarter. Baillie Gifford & Co. now owns 641,120 shares of the company’s stock worth $12,130,000 after acquiring an additional 91,120 shares during the last quarter. Finally, Sofinnova Ventures Inc bought a new stake in NuCana in the 1st quarter worth $88,293,000. Institutional investors own 24.42% of the company’s stock.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
Read More: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.